Latest filing published 19 Sept 2007 for CADENCE PHARMACEUTICALS INC, €10k.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
ProQuest Investments III, L.P.: trading record in brief
Filings by ProQuest Investments III, L.P. span 2 companies, the busiest being Cadence Pharmaceuticals Inc and Novadel Pharma Inc. The record holds 199 filings, for trades running from 30 October 2006 to 19 September 2007.
On the open market, the record shows 1 purchase worth €853k and 195 sales worth €2.6M. Netting one side against the other leaves €1.8M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 option exercise. So far in 2007, the count stands at 1 purchase and 195 sales.
The newest entry dates from 19 September 2007: an open-market sale of €10k, in Cadence Pharmaceuticals Inc. The last insider purchase was made public on 26 January 2007, 7,226 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to ProQuest Investments III, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,000 shares@ US$14.09Common StockSEC:0001209191-07-054306:0
- 100 shares@ US$14.08Common StockSEC:0001209191-07-054306:1
- 752 shares@ US$14.07Common StockSEC:0001209191-07-054306:2
- 1,202 shares@ US$14.06Common StockSEC:0001209191-07-054306:3
- 16,811 shares@ US$14.05Common StockSEC:0001209191-07-054306:4
- 100 shares@ US$14.04Common StockSEC:0001209191-07-054306:5
- 100 shares@ US$14.03Common StockSEC:0001209191-07-054306:6
- 200 shares@ US$14.02Common StockSEC:0001209191-07-054306:7
- 600 shares@ US$14.01Common StockSEC:0001209191-07-054306:8
- 36,235 shares@ US$14.00Common StockSEC:0001209191-07-054306:9
- 100 shares@ US$13.97Common StockSEC:0001209191-07-054306:10
- 17,100 shares@ US$13.50Common StockSEC:0001209191-07-054306:11
- 200 shares@ US$13.50Common StockSEC:0001209191-07-054305:0
- 7,900 shares@ US$13.50Common StockSEC:0001209191-07-054305:1
- 200 shares@ US$14.59Common StockSEC:0001209191-07-054305:2
- 700 shares@ US$14.57Common StockSEC:0001209191-07-054305:3
- 400 shares@ US$14.56Common StockSEC:0001209191-07-054305:4
- 300 shares@ US$14.55Common StockSEC:0001209191-07-054305:5
- 300 shares@ US$14.54Common StockSEC:0001209191-07-054305:6
- 100 shares@ US$14.53Common StockSEC:0001209191-07-054305:7
- 100 shares@ US$14.51Common StockSEC:0001209191-07-054305:8
- 100 shares@ US$14.45Common StockSEC:0001209191-07-054305:9
- 400 shares@ US$14.44Common StockSEC:0001209191-07-054305:10
- 400 shares@ US$14.41Common StockSEC:0001209191-07-054305:11
- 5,685 shares@ US$14.40Common StockSEC:0001209191-07-054305:12
25 of 199 declarations